Literature DB >> 12118754

Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy.

Noritoshi Nagaya1, Motomi Ando, Hideo Oya, Yutaka Ohkita, Shingo Kyotani, Fumio Sakamaki, Norifumi Nakanishi.   

Abstract

BACKGROUND: Plasma brain natriuretic peptide (BNP), a cardiac hormone secreted mainly by the cardiac ventricles, has been shown to increase in proportion to the degree of cardiac overload. However, whether plasma BNP may serve as a marker for the efficacy of pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension remains unknown.
METHODS: Plasma BNP level was measured in 34 patients with chronic thromboembolic pulmonary hypertension before and 1 month after pulmonary thromboendarterectomy. Right heart catheterization was also performed before and 1 month after the operation.
RESULTS: Preoperative plasma BNP level was significantly elevated in patients with chronic thromboembolic pulmonary hypertension compared with control patients (246 +/- 40 vs 13 +/- 2 pg/mL; p < 0.001; n = 34) and was positively correlated with total pulmonary resistance (r = 0.57; p < 0.001). After pulmonary thromboendarterectomy, plasma BNP level in survivors markedly decreased (220 +/- 31 to 54 +/- 9 pg/mL; p < 0.001; n = 32) in association with a reduction of total pulmonary resistance (15.6 +/- 1.0 to 4.5 +/- 0.3 Wood units; p < 0.001). The change in plasma BNP level was closely correlated with that in total pulmonary resistance (r = 0.63; p < 0.001). Importantly, a sustained elevation of plasma BNP (> or = 50 pg/mL) indicated the presence of residual pulmonary hypertension (> or = 5 Wood units) after operation (sensitivity = 73%; specificity = 81%).
CONCLUSIONS: Plasma BNP level was strongly associated with the severity of pulmonary hypertension in patients with chronic thromboembolic pulmonary hypertension and thereby may serve as a noninvasive marker for the efficacy of pulmonary thromboendarterectomy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118754     DOI: 10.1016/s0003-4975(02)03654-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  20 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

2.  B-type natriuretic peptide and weaning from mechanical ventilation.

Authors:  Armand Mekontso-Dessap; Nicolas de Prost; Emmanuelle Girou; François Braconnier; François Lemaire; Christian Brun-Buisson; Laurent Brochard
Journal:  Intensive Care Med       Date:  2006-08-29       Impact factor: 17.440

3.  Noninvasive pulmonary artery pressure monitoring by EIT: a model-based feasibility study.

Authors:  Martin Proença; Fabian Braun; Josep Solà; Jean-Philippe Thiran; Mathieu Lemay
Journal:  Med Biol Eng Comput       Date:  2016-09-17       Impact factor: 2.602

4.  Plasma brain natriuretic peptide as a biomarker for haemodynamic outcome and mortality following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.

Authors:  Sulaiman Surie; Herre J Reesink; Mart N van der Plas; Maxim Hardziyenka; Jaap J Kloek; Aeilko H Zwinderman; Paul Bresser
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-20

5.  Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.

Authors:  Robert P Frantz; Harrison W Farber; David B Badesch; C Greg Elliott; Adaani E Frost; Michael D McGoon; Carol Zhao; David R Mink; Mona Selej; Raymond L Benza
Journal:  Chest       Date:  2018-01-31       Impact factor: 9.410

Review 6.  B-type natriuretic Peptide and the right heart.

Authors:  Lok Bin Yap
Journal:  Heart Fail Rev       Date:  2004-04       Impact factor: 4.214

7.  Clinical and haemodynamic evaluation of chronic thromboembolic pulmonary hypertension patients scheduled for pulmonary thromboendarterectomy: Is schistosomiasis hypertension an important confounding factor?

Authors:  Mario Terra-Filho; Marcos Figueiredo Mello; Mônica Silveira Lapa; Ricardo Henrique Oliveira Braga Teixeira; Fábio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

8.  Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.

Authors:  Francesco Dentali; Marco Donadini; Monica Gianni; Andrea Bertolini; Eva Lonn; Achille Venco; Gianpaolo Cattozzo; Walter Ageno
Journal:  Intern Emerg Med       Date:  2009-02-27       Impact factor: 3.397

9.  Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study.

Authors:  Yonghua Chen; Chunli Liu; Wenju Lu; Mengxi Li; Cyrus Hadadi; Elizabeth Wenqian Wang; Kai Yang; Ning Lai; Junyi Huang; Shiyue Li; Nanshan Zhong; Nuofu Zhang; Jian Wang
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.